The erectile dysfunction drugs market is expected to register a CAGR of nearly -3.40% during the forecast period with a revenue of approximately USD 3,625 million in 2020 and projected to decrease to USD 2,948 million by 2026.
The severe shortage of critical medical needs and the rapid increase in the number of cases of COVID-19 cases have led to a shift in the progress of health facilities. Tourism restrictions and the supply chain disruption have created a small negative impact on market players, leading to severe drug shortages in global markets. Lockdown and government restrictions has hampered the export and import of drugs across the countries due to the shortage of medicines, with many people being denied access to drugs.
Some factors which drive the erectile dysfunction (ED) drug market include the adoption of a sedentary lifestyle and its associated stress, rising geriatric population, and the comorbidity between erectile dysfunction and heart disease, and diabetes. A sedentary lifestyle, alcoholism and smoking greatly increase the risk of erectile dysfunction. Increased acceptance of these negative lifestyle decisions will lead to the full growth of the erectile drug market.
Erectile dysfunction is the most common risk factor in men and its incidence increases with age. Ageing and older men frequently have comorbidities, like diabetes mellitus, chronic obstructive pulmonary disease, hypertension, and cardiovascular diseases, etc., likewise, they concurrently refer to a clinician for impairments in sexual function, mostly for erectile dysfunction (ED).
The rise within the number of ED cases are often correlated with the high growth of obesity, diabetes, and cardiovascular disorders. Hypertension is additionally another major illness linked to male erecticle dysfunction and as reported by CDC in 2018, the prevalence of hypertension has grown at a substantial rate, with approximately 65 million people affected by the condition within the United States.
However, the patints are reluctant to seek treatment, this factor is restarining the market growth. Generally, ED is considered as a physical problem, and it is also due to poor psychological health. Most patients suffering from erectile dysfunction do not choose treatment options. This is a direct result of social stigma associated with erectile dysfunction. In a number of low- and middle-income countries, social discrimination is particularly prevalent, where men and women suffer from silent sexual dysfunction, shame, guilt, and negligence / ignorance. Since ED is associated with a number of chronic diseases, the vast majority of people are affected by the disease, treatment is mainly for chronic diseases, and patients often hide their sexual dysfunction. In addition, the intense competition offered by generic drugs with branded products greatly reduces market growth. Most of the branded products especially Pfizer's viagra has lost its patent rights nad many generics have eveovled since then, posing a great threat to the declining growth of the market. As a result of these factors the market is experiencing a slowdown in growth.
Key Market Trends
Viagra (sildenafil citrate) is Expected to Dominate the Market in the Forecast Period
The overall impact on bulk supply is reported to be overwhelming, in all drugs and elsewhere countries. Extended controls from the implementation of measures to combat the spread of COVID-19 have had a two-pronged effect on the supply of bulk supply of drugs. Some countries, such as Italy, as well as Central Asian countries, have experienced a sharp decline in drug supply.
Sildenafil, sold in the brand name Viagra, among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. Its effectiveness for treating sexual dysfunction in women has not been demonstrated. Sildenafil (Viagra) is the most common drug used as first-line therapy in the treatment of erectile dysfunction.
Sildenafil (Viagra) is the most effective when taken on an empty stomach one hour before sex. It's effective for four to five hours or more if you have mild to moderate erectile dysfunction. In June 2019, Lupin has received approval for its Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc's Viagra Tablets, 25 mg, 50 mg, and 100 mg.
Only 21 years after it was discovered, the sale of a prestigious drug has declined. Pfizer lost exclusive rights to the drug in December 2017, bringing floods of generic drugs. The sales of the drug fell 73 percent a year in 2018 from USD 789 million to USD 217 million, Pfizer said in a fourth-quarter financial report, the sales of the drug came down due to the generics that entered the market. In addition, barriers such as the patient's neglect in relation to the disease, stagnant growth without progress in the segment reduces partial growth
North America is Expected to Dominate the Market
North America is expected to dominate the erectile dysfunction drugs market, owing to the rising geriatric population, increase in cases of ED, and the presence of better healthcare infrastructure. According to the United States Census Bureau's Statistics as of 2020, the total number of men aged 60-65 was recorded to be 9.86 million. The rise in the geriatric men population is expected to increase the number of patients suffering from ED, as it is very common in men above age 40. The availability of various ED drugs through over-the-counter (OTC) and online channels is a key factor for the dominance of these regions.
According to the results of the research conducted by Dimension Clinic, this health problem affects about 6 million men in Mexico. Meanwhile, only about 15% of them turn for medical help to normalize the sex life.
There are some companies making advancements, in terms of time taken by patients to take the pill before sexual activity. Lupin launched Sildenafil tablets, a generic version of Pfizer's Viagra, used for the treatment of erectile dysfunction, in the US market in 2019. In the case of the United States, several companies collaborate with domestic players having extensive market in the country. Thus, companies get exclusive rights for marketing, which benefits this market significantly.
The market studied is a fragmented market owing to the presence of the various small and large market players. Some of the market players are Apricus Biosciences, Inc., Bayer AG, Eli Lilly and Company, Ferring Pharmaceuticals, GlaxoSmithKline plc., Metuchen Pharmaceuticals, LLC, Pfizer Inc., S.K. Chemicals Co. Ltd., Teva Pharmaceutical Industries Ltd., and VIVUS, Inc.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Rising Adoption of a Sedentary Lifestyle Along with the Associated Stress
- 4.2.2 Rising Geriatric Population
- 4.2.3 Comorbidity between Erectile Dysfunction and Heart Diseases, and Diabetes
- 4.3 Market Restraints
- 4.3.1 Reluctance of Patients to Seek Treatment
- 4.3.2 Poor Patient Adherence to ED Drugs
- 4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Product
- 5.1.1 Viagra (sildenafil citrate)
- 5.1.2 Cialis (Tadalafil)
- 5.1.3 Levitra/Staxyn (vardenafil)
- 5.1.4 Stendra/Spedra (avanafil)
- 5.1.5 Zydena (udenafil)
- 5.1.6 Vitaros (Alprostadil Cream)
- 5.1.7 Other Products
- 5.2 By Distribution Channel
- 5.2.1 Hospital Pharmacies
- 5.2.2 Retail Pharmacies
- 5.2.3 Online Pharmacies
- 5.3 Geography
- 5.3.1 North America
- 188.8.131.52 United States
- 184.108.40.206 Canada
- 220.127.116.11 Mexico
- 5.3.2 Europe
- 18.104.22.168 Germany
- 22.214.171.124 United Kingdom
- 126.96.36.199 France
- 188.8.131.52 Italy
- 184.108.40.206 Spain
- 220.127.116.11 Rest of Europe
- 5.3.3 Asia Pacific
- 18.104.22.168 China
- 22.214.171.124 Japan
- 126.96.36.199 India
- 188.8.131.52 Australia
- 184.108.40.206 South Korea
- 220.127.116.11 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 18.104.22.168 GCC
- 22.214.171.124 South Africa
- 126.96.36.199 Rest of Middle East and Africa
- 5.3.5 South America
- 188.8.131.52 Brazil
- 184.108.40.206 Argentina
- 220.127.116.11 Rest of South America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Apricus Biosciences Inc.
- 6.1.2 Bayer AG
- 6.1.3 Eli Lilly and Company
- 6.1.4 Ferring Pharmaceuticals
- 6.1.5 GlaxoSmithKline plc.
- 6.1.6 Metuchen Pharmaceuticals LLC
- 6.1.7 Pfizer Inc.
- 6.1.8 S.K. Chemicals Co. Ltd
- 6.1.9 Teva Pharmaceutical Industries Ltd
- 6.1.10 VIVUS Inc.
- 6.1.11 Lupin Limited
7 MARKET OPPORTUNITIES AND FUTURE TRENDS